Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/YZacks Investment Research • 11/07/25
Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/06/25
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonPRNewsWire • 10/30/25
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/30/25
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial MarketsPRNewsWire • 10/28/25
Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High?Zacks Investment Research • 10/28/25
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific MeetingPRNewsWire • 10/22/25
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall StreetThe Motley Fool • 10/13/25
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?The Motley Fool • 09/21/25
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025PRNewsWire • 09/18/25
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025PRNewsWire • 09/09/25
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/25